Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
To the Editor: In reporting the results of the Trial to Evaluate Cardiovascular and Other Longterm Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6), Marso et al. (Nov.10 issue) 1 describe a lower rate of cardiovascular events among patients with type 2 diabetes mellitus who received the glucagon-like peptide 1 (GLP-1) analogue semaglutide than among patients who received placebo.Their results are consistent with those in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, 2 which assessed the effects of another GLP-1 analogue, liraglutide.In SUSTAIN-6, the use of insulin at trial entry was similar between the two groups.However, during the LEADER trial, the use of insulin was approximately two times higher in the placebo group than in the liraglutide group, and during SUSTAIN-6, the use of insulin was approximately three times higher in the placebo group than in the semaglutide group.The significantly greater use of insulin in the placebo groups in these two trials may, at least in part, explain the increase in the risk of death from any cause as well as the increase in the risks of heart failure, cardiovascular events, renal failure, and hypoglycemia in these two groups.Hazard ratios for these events associated with increased use of insulin range from 1.23 to 4.57, as shown in two cohort studies in primary care. 3,4Thus, we wonder whether the greater use of insulin in the placebo groups than in the liraglutide and semaglutide groups during these trials may have amplified the beneficial effects of liraglutide and semaglutide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationBasal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Early Worsening of Diabetic Retinopathy in the Diabetes Control and Complications Trial
(1998) · Archives of Ophthalmology · doi:10.1001/archopht.116.7.874 · Cited by 509
Research works printed but not linked: 6
- 10.1136/bmj.i3477 · DOI · Paper page
- 10.1136/bmj.i1450 · DOI
- 10.1016/j.diabres.2013.03.018 · DOI · Paper page
- 10.2337/diacare.18.12.1571 · DOI
- 10.2337/diacare.28.12.2819 · DOI
- 10.1056/NEJMoa1603827 · DOI · Paper page
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Gornik, H. L., Aronow, H. D., Goodney, P. P., Arya, S., Brewster, L. P., Byrd, L., Chandra, V., Drachman, D. E., Eaves, J. M., Ehrman, J. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001251 · Cited by 771
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000691 · Cited by 639
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Metadata
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-03-02
- Volume
- 376
- Issue
- 9
- Pages
- 890-892
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3049003652
- Cited by
- 144
- References
- 4
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.